Compare stocks

UnitedHealth Group Incorporated (UNH) vs CVS Health Corp. (CVS)

UNH leads on margins, balance sheet and momentum; CVS on valuation and earnings surprises

UnitedHealth (UNH) and CVS Health (CVS) share a sector and industry but differ in model: premiums were 78.70% of UNH's fiscal 2025 revenue, while pharmacy was 58.85% of CVS's. Qanvo's scorecard favors UNH on profitability and quality (100 versus 0), financial resilience (80 versus 20) and technical momentum (100 versus 0). It favors CVS on valuation (83 versus 17) and earnings momentum (100 versus 0). Growth and lower risk are mixed with 50 each, so there is no clear leader. CVS trades at a forward P/E of 9.94× versus 16.88× for UNH, while UNH has the higher margins and lower leverage. Forward P/E and EPS growth are analysts' estimates.

Business overview

Both companies sit in Healthcare and the Medical - Healthcare Plans industry on the NYSE. UnitedHealth Group is the larger at a market cap of $351.49B (Mega tier) versus $110.01B for CVS Health (Large tier). Per its profile, UnitedHealth operates four segments: UnitedHealthcare, Optum Health, Optum Insight and Optum Rx, and describes itself as a comprehensive healthcare enterprise across the United States. CVS describes itself as a health solutions company with segments for Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. Its profile includes PBM solutions, medical clinics and retail pharmacies that dispense prescriptions. The revenue mix shows a real difference in model. For fiscal 2025, premiums were 78.70% of UnitedHealth revenue, while pharmacy revenue was 58.85% of CVS revenue and premiums 34.63%. UnitedHealth is therefore weighted toward insurance, CVS toward pharmacy dispensing. The profiles do not give a geographic split beyond UnitedHealth's US description.

  • UnitedHealth's market cap of $351.49B is more than three times CVS's $110.01B.
  • Premiums were 78.70% of UnitedHealth's fiscal 2025 revenue versus 34.63% at CVS.
  • Pharmacy revenue was 58.85% of CVS's fiscal 2025 revenue, a segment UnitedHealth does not report in the same way.
  • Ratios such as gross margin are shaped by these different mixes and compare only loosely.

Valuation

CVS is cheaper on every headline multiple, and Qanvo's scorecard names it the valuation leader (83 versus 17). Trailing P/E is 9.95× for CVS versus 22.13× for UnitedHealth. Forward P/E, based on analyst estimates, is 9.94× versus 16.88×. Price/sales is 0.26× versus 0.78×, EV/EBITDA 8.65× versus 14.19×, and PEG 1.92× versus 1.23×, the one measure where UnitedHealth is lower. Free-cash-flow yield is 14.15% for CVS versus 6.49%. Against its own 5-year range, UnitedHealth's trailing P/E of 22.13× sits below its median of 26.07× within a 10.45× to 39.75× range. CVS at 9.95× is just under its 5-year minimum of 9.99× (median 18, maximum 211.47×, inflated by depressed earnings). Against sector peers, UnitedHealth's trailing P/E is at the 29th percentile (sector median 30.02×) and CVS's at the 3rd. The discount may partly reflect CVS's lower margins and ROIC, higher leverage and a steeper recent share-price swing, though it also has stronger near-term revenue growth.

  • CVS trades at a forward P/E of 9.94× versus 16.88× for UnitedHealth.
  • CVS's free-cash-flow yield of 14.15% is more than double UnitedHealth's 6.49%.
  • UnitedHealth's PEG of 1.23× is below CVS's 1.92×, reflecting its higher expected EPS growth.
  • CVS's trailing P/E of 9.95× is at the 3rd sector percentile versus the 29th for UnitedHealth.

Growth

Qanvo's growth scorecard is mixed, 50 each, so there is no clear leader. CVS grew revenue faster over the last year (6.73% versus 3.33%) and last quarter (5.37% versus -0.41%). UnitedHealth leads on the 3-year revenue compound rate (11.35% versus 7.63%). Reported EPS growth is distorted for both: UnitedHealth is -8.55% year on year (76.06% last quarter) and -14.52% over three years, while CVS shows 2,160.53% off a depressed base and -24.73% over three years. Annual history: UnitedHealth revenue rose from $400.28B in 2024 to $447.57B in 2025, but EPS fell from 15.51 to 13.23. CVS revenue rose from $372.81B to $402.07B, with EPS dropping from 3.66 to 1.39. Quarterly, CVS swung from a loss (EPS -3.13 in Q3 FY2025) to 1.68 in Q3 FY2026, while UnitedHealth's quarterly EPS fell from 6.90 in Q1 to 4.56 in Q3 FY2026. Analyst estimates: expected EPS growth next fiscal year is 13.70% for UnitedHealth versus 5.19% for CVS. Consensus EPS for the current fiscal year is 20.60 versus 8.25.

  • CVS's last-year revenue growth of 6.73% is about double UnitedHealth's 3.33%.
  • UnitedHealth's 3-year revenue CAGR of 11.35% beats CVS's 7.63%.
  • Analysts estimate next-year EPS growth of 13.70% for UnitedHealth versus 5.19% for CVS.
  • Both show negative 3-year EPS growth: -14.52% for UnitedHealth and -24.73% for CVS.

Profitability, cash flow & financial health

UNH leads Qanvo's profitability and quality category with a score of 100 against 0 for CVS (relative ranks within this pair only). Margins explain much of it: gross margin is 22.81% for UNH versus 14.23% for CVS, operating margin 5.32% versus 3.58%, and net margin 3.53% versus 2.63%. Returns follow: ROIC is 13.14% versus 8.44%, and ROE 16.39% versus 14.41%. Gross margins are not fully comparable, because CVS has a large pharmacy and retail mix and UNH is weighted to premiums. On cash, UNH produced free cash flow of $22.83B (FCF margin 5.08%) against $15.57B for CVS (3.70%). Direction of travel differs: CVS operating margin changed by 2.33% over the year, while UNH's changed by -0.74%. CVS free cash flow growth was 147.37% versus 31.40% for UNH, though CVS is recovering from a weak base, with a loss in Q3 FY2025. On the balance sheet, UNH has net debt/EBITDA of 1.64× versus 3.07×, debt/equity of 0.76× versus 0.94×, and interest coverage of 6.21× versus 4.91×. Both have current ratios below 1 (0.74× and 0.85×), so liquidity is tight for each; CVS is slightly higher.

  • UNH's operating margin is 5.32% versus 3.58% for CVS, and its ROIC is 13.14% versus 8.44%.
  • UNH's free cash flow is $22.83B (5.08% margin) versus $15.57B (3.70%) for CVS.
  • UNH's net debt/EBITDA is 1.64× versus 3.07× for CVS, and its interest coverage is 6.21× versus 4.91×.
  • CVS's operating margin improved 2.33% over the year while UNH's slipped 0.74%, narrowing the gap somewhat.

Shareholder returns & capital allocation

CVS offers the higher dividend yield at 3.10% versus 2.32% for UNH, and its payout ratio is lower at 30.97% versus 51.71%, which leaves CVS more earnings coverage per dollar paid. UNH's dividend per share is $9.06 over the trailing twelve months, versus $2.66 for CVS. The quarterly payment is $2.32 at UNH and $0.665 at CVS. Dividend growth favors UNH: three-year dividend growth is 10.90% with 16 years of growth, against 6.53% and 0 years of growth for CVS, whose quarterly payment of $0.665 has been flat across the eight payments listed. On share count, UNH's shares changed by -1.10% over the year, consistent with buybacks, and it repurchased $5.54B of stock in fiscal 2025 alongside $7.92B of dividends. CVS shares changed by 1.73%, a modest increase, and it repurchased nothing in fiscal 2025 while paying $3.40B in dividends. UNH is therefore returning cash through both channels, while CVS relies on its dividend alone, with debt of $75.30B for CVS alongside $74.33B for UNH.

  • CVS yields 3.10% versus 2.32% for UNH, with a payout ratio of 30.97% versus 51.71%.
  • UNH has raised its dividend for 16 years with 10.90% three-year growth, versus 0 years and 6.53% for CVS.
  • UNH's share count fell 1.10% over the year while CVS's rose 1.73%.
  • UNH repurchased $5.54B of stock in fiscal 2025, versus none at CVS.

Earnings intelligence

Both companies beat EPS consensus in each of the last four reported quarters, but CVS did so by wider margins and with larger revenue beats. CVS's EPS surprises were 26.67% (Nov 4, 2026), 39.46%, 17.89% and 9.00%, with revenue surprises of 3.51%, 6.07%, 5.72% and 1.92%. UNH's EPS surprises were 13.29% (Oct 13, 2026), 29.94%, 9.88% and 0.48%, with revenue surprises of 1.25%, 1.11%, 2.09% and -0.49%. The beat streak is 8 quarters for CVS and 5 for UNH. The stock reactions diverged from the beats. CVS fell 11.03% after its latest report and 7.85% after the one before, despite beating. UNH rose 4.52% and 1.81% after its last two, but fell 16.39% after the January 2026 report, when its EPS beat was only 0.48%. Analysts' estimate revisions over 30 days are upward for both: EPS 2.88% for CVS versus 1.11% for UNH. Next reports: UNH on Jan 20, 2027 and CVS on Feb 9, 2027, both before the open and neither confirmed. A news headline says UNH raised guidance, but the facts give no guidance figures. Qanvo's scorecard gives CVS the earnings momentum lead (100 versus 0), and the latest report reinforced that, even though the price reaction was negative.

  • CVS's latest EPS surprise was 26.67% versus 13.29% for UNH.
  • CVS has beaten EPS estimates 8 quarters in a row versus 5 for UNH.
  • After their latest reports, CVS fell 11.03% while UNH rose 4.52%.
  • Analysts' 30-day EPS revisions are 2.88% for CVS versus 1.11% for UNH.

Technicals, relative performance & risk

UNH leads on most recent price performance. Price returns over 1 month are -4.2% for UNH versus -7.4% for CVS; over 3 months, -1.5% versus -8.7%; over 6 months, -0.4% versus -10.6%; and over 1 year, 21.6% versus 9.4%. With dividends, the 1-year figures are 24.8% and 12.0%. Over longer spans CVS leads: 3-year price return is 25.7% versus -27.2% for UNH, and 5-year total return is 8.6% versus -5.0%. Both sit below their 20-day averages (-4.14% UNH, -3.47% CVS) and have RSI near 43 (42.92 and 43.65). UNH is 6.01% above its 200-day average and 0.47% below its 50-day, while CVS is 3.90% below both. UNH's relative strength rating is 87 versus 61. UNH is 15.58% below its 52-week high and CVS 22.47% below its. Risk is split. CVS's 30-day volatility is 49.22% versus 31.52% for UNH, and its beta is -0.03 versus 0.34. One-year maximum drawdowns are close at -27.70% and -27.29%. Technicals favor UNH, while CVS leads on valuation and earnings momentum in the scorecard, so the signals conflict.

  • UNH's 1-year price return of 21.6% is above CVS's 9.4%, but CVS's 3-year return of 25.7% is above UNH's -27.2%.
  • UNH trades 6.01% above its 200-day average while CVS is 3.90% below it.
  • CVS's 30-day volatility of 49.22% compares with 31.52% for UNH.
  • Relative strength rating is 87 for UNH versus 61 for CVS.

Analyst & ownership sentiment

Analysts' opinions are favorable on both, and these are opinions, not facts about the future. UNH carries a consensus label of Buy with a rating score of 2.25 from 18 analysts, while CVS is also Buy at 2.2 from 15 analysts. The mean target price is $478.25 for UNH, implying 22.73% upside, versus 111.00 for CVS, implying 29.36%. CVS therefore shows more target upside, though the gap is modest. In the latest consensus tally, UNH has 43 Buy, 7 Hold and 2 Sell ratings, while CVS has 2 Strong Buy, 33 Buy and 6 Hold with no Sells. Recent estimate revisions favor CVS: EPS revisions over 30 days are 2.88% versus 1.11% for UNH. Neither had upgrades or downgrades in the last 30 days. Institutions hold 88.55% of UNH and 90.26% of CVS, with 3-month changes of 6.31% and 3.39%. Filings lag by weeks, so these may be dated. Insiders differ: UNH had one sale in 90 days (net -455.9K), while CVS had one buy (net 2.0M). Short interest is low for both: 1.55% of float for UNH and 1.39% for CVS, though CVS short interest rose 10.39% in the latest period against -0.31% for UNH.

  • Mean analyst target upside is 29.36% for CVS versus 22.73% for UNH, as opinions.
  • 30-day EPS revisions are 2.88% for CVS versus 1.11% for UNH.
  • Insiders net bought 2.0M at CVS but net sold 455.9K at UNH over 90 days.
  • Short float is 1.39% for CVS versus 1.55% for UNH, with CVS short interest up 10.39%.

Risks & catalysts

Valuation and estimates matter differently. UNH trades at a forward P/E of 16.88×, exactly at its industry median, and a PEG of 1.23×, while CVS sits at 9.94× forward and 1.92× PEG. CVS's cheapness reflects lower expected EPS growth next year (5.19% versus 13.70% for UNH), and both depend on analyst estimates holding. UNH's history shows how sharp reactions can be: its earnings-day moves reached -27.30% and -16.39% in the last eight reports, and its 1-year maximum drawdown is -27.29%. CVS's is -27.70%, and its last earnings move was -11.03%. Leverage favors UNH: net debt/EBITDA of 1.64× versus 3.07× for CVS, and interest coverage of 6.21× versus 4.91×. CVS's 30-day historical volatility is 49.22%, against 31.52% for UNH. Margins are thinner at CVS (operating 3.58% versus 5.32%), though UNH's operating margin fell 0.74% over a year. Catalysts: UNH has an ex-dividend date on Dec 7, 2026 and unconfirmed earnings on Jan 20, 2027. CVS's next earnings are unconfirmed for Feb 9, 2027. News also mentions a CVS planned split, with execution risk noted by a publisher.

  • CVS's net debt/EBITDA is 3.07× versus 1.64× for UNH.
  • CVS's 30-day volatility is 49.22% versus 31.52% for UNH.
  • UNH's next earnings are expected Jan 20, 2027 and CVS's Feb 9, 2027, both unconfirmed.
  • UNH's ex-dividend date is Dec 7, 2026, and its largest earnings-day drop in eight reports was -27.30%.

Analysis written November 18, 2026. AI-generated, for information only; not investment advice.